Brief: BioInvent Gets FDA Ind Approval For Anti-Fcyriib Antibody BI-1607

BioInvent International AB

18/11/2022 07:21

Nov 18 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT RECEIVES FDA IND APPROVAL FOR ANTI-FCYRIIB
ANTIBODY
BI-1607
    * ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS
APPROVED
ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ITS
FCYRIIB-BLOCKING ANTIBODY BI-1607
    * BI-1607 IS INTENDED TO ENHANCE EFFICACY AND OVERCOME
RESISTANCE
TO EXISTING CANCER TREATMENTS SUCH AS TRASTUZUMAB
    * IND APPROVAL ALLOWS FOR A PHASE 1/2A TRIAL WITH BI-1607,
IN
COMBINATION WITH TRASTUZUMAB IN HER2+ SOLID TUMORS, TO BE
EXTENDED TO U.S. CENTERS

Source text for Eikon:  ID:nMFN9Vc56f 
Further company coverage:  BINV.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))